Awesome Article on Dr. Bruce

New Post Public Reply Private Reply Replies (2) Message Board
thriftycents
2,005
Awesome Article on Dr. Bruce Patterson

https://www.bizjournals.com/sanfrancisco/c/ho...early.html

How Peninsula biotech CEO navigated early HIV research before his work on Covid-19 - San Francisco Business Times
Todd Johnson | San Francisco Business Times
6-7 minutes

By Ron Leuty
– Staff Reporter, San Francisco Business Times

May 1, 2020, 1:44pm PDT

Dr. Bruce Patterson has seen this story before: A virus snakes its way into the population, killing thousands and throwing scientists headlong into the pursuit for any sort of treatment, let alone a vaccine or cure. Back during the emergence of the AIDS virus, Chicago-born-and-raised Patterson was a viral researcher in the early days of molecular biology doing the fundamental studies to figure out how the disease worked. “This isn’t my first pandemic,” he says. During this crisis, however, he is the founder and CEO of IncellDx Inc., a San Carlos-based diagnostics company that could play a major role in getting Covid-19 patients on a particular drug quickly. The company is ramping up its activities in the face of the coronavirus pandemic through its work with Vancouver-based CytoDyn Inc. and that company’s Covid drug candidate leronlimab.

How do you describe what IncellDx does? IncellDx has 87 patents for technology that allows molecular diagnostics in a cell without destroying the cell. New sequencing technologies put cells and tissue in a blender and answer the question, “What’s there?” We know how much is there, what’s it in and how it will respond to drugs. That links to pharma because it provides context into pathways. Basically, we do personalized cellular medicine.

What kind of timeframe are we talking about for these tests? We do what everyone does in solution but in the cell, and we get an answer in two to four hours, rather than three weeks. That makes a difference. I had a clinician tell me, “Some people with stage IV lung cancer don’t have two or three weeks to answer which therapy works for them.”

How was the company funded? We built the company on sales, not on big money raises and venture capital. The best way was to bootstrap, quickly prototype a product, get it in the hands of thought leaders, show its significance and promise and then do strategic deals with reference labs and pharma companies. Some would argue it’s a slower path, but we got to profitability relatively quickly.

What does your growth look like in terms of hiring? We’re looking to put people to work in areas like data entry, shipping, handling, all in support of clinical trials. When we get approval, we will need to scale massively. We will be selling these as a kit worldwide, once CytoDyn tells us where to go.

How was it moving from academia to business? It’s one of the hardest transitions ever, but now I can tell an academic from a business person from a mile away. You have to resist the temptation to want to look at the deepest levels of mechanism when you discover something. In business, it’s how quickly you can get a provisional patent. Instead of “why is this happening?” it’s “this happens, it’s reproducible and we can make a kit out of it.”

What’s been your most important lesson? In 1990, I was using colloidal gold in culture with HIV. It was a therapy for arthritis and it stopped the virus cold. I remember going home to my wife and saying, “I think I just locked up the Nobel Prize.” Now, I see studies where they put lice medicine in culture with Covid and it stopped the virus cold and I have flashbacks. We’ll see. I never want to dash innovation or hope, but after a while you have the experience after having worked in pandemics. The message is “the body isn’t a flask of cells.”

What advice would you give the president on the crisis? I would say there’s a way to phase reopening based on the serologic tests. They have to use rapid serology tests that, hopefully, patients can do at home and are confirmed by more-sophisticated tests.

Who is your mentor? My aunt (Mary Christensen). She was one of the first virologists in the 1960s and later head of virology at Children’s Memorial Hospital in Chicago when I was in virology at Northwestern University. We overlapped a few years before she retired. She could grow any virus any day in any culture and do analysis of it. She was really a trend-breaker and a leader in the field.

What would you do if you had to change careers? I would race sailboats. It’s a chess match on water. The reason Larry Ellison and other smart people go into sailing is that it satisfies a profound intellectual urge while rolling in a physical aspect. It’s a great release: You can’t think of anything else while your body is hanging over the edge of a sailboat going 25 miles per hour and trying to figure out where to go next.

Where is IncellDx in five years? We won’t be around. We’ll be under some other umbrella we do and be bought out and join with some larger group with a broader reach. We have a full portfolio of oncology assays on top of Covid, HPV, HIV and others. Our approach of looking at cells one at a time is being validated.

Dr. Bruce Patterson

CEO, IncellDx Inc.

Education: B.S. from the University of Michigan; M.D. from Northwestern University

The Resume: Chief resident of pathology at Northwestern Memorial Hospital; associate professor and director of diagnostic virology at Stanford University

Reading list: I read books to escape. I love Stephen King, stories that have great character definition. It’s about getting away from it a little bit.

Favorite restaurant: Evvia Estiatorio in Palo Alto and Coqueta in San Francisco

INCELLDX INC.

HQ: San Carlos

Employees: 20

Founded: 2009

What it does: Diagnostics company that quickly identifies within a cell whether a gene, for example, is there.

Recent work: The company has focused on Covid-19 amid the pandemic, developing a companion diagnostic for CytoDyn Inc.'s leronlimab, an experimental HIV and cancer drug repurposed to treat patients with respiratory complications.

The (New) Routine

Patterson explained how his schedule has changed amid the pandemic:

Less family time, but more exercising with them

Less sailing and less working out

Less eating as he limits grocery store visits

More writing of research articles

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lake Ridge Sets $0.68 Dividend as 2026 Payouts Rise

Updated Category News Views 146

A community bank raising its cash return is not fireworks, but it gets my attention faster than another glossy growth slogan. Lake Ridge Bancorp has declared a fourth-quarter 2026 dividend of $0.68 per share, payable December 16 to shareholders of record on November 30. That is a plain, useful announcement from OTCQX:LRBI, and plain is often underrated when you are...

Continue Reading
Zoomlion’s Australian Service Push Looks Built to Last

Updated Category News Views 54

Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...

Continue Reading
Satellite NTN's $3.22B Promise Needs Real Receipts

Updated Category News Views 17

Dead zones over oceans, deserts, and flight paths are finally becoming a serious commercial problem, not merely a neat engineering demo. That is the muscle behind the satellite non-terrestrial network, or NTN, pitch: connect aircraft, vessels, remote assets, and scattered sensors where terrestrial networks simply do not reach. MarketsandMarkets projects this market will...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 135

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading
Zoomcar's November 23 Report Puts Execution on Trial

Updated Category News Views 73

A Date on the Board, Not a Verdict November 23 is when Zoomcar finally has to put some fresh numbers beside the story. The Bengaluru-based peer-to-peer car-sharing marketplace says it will release second-quarter fiscal 2027 financial and operating results that Monday, covering the quarter ended September 30, 2026. Management also plans a live webcast at 8:00 a.m. Eastern...

Continue Reading
Valley Family Health Breach Notice Raises Hard Questions

Updated Category News Views 142

Seven months is a long time for sensitive patient data to sit inside an unresolved security story. Valley Family Health Care, Inc. says it suffered a network disruption on or about March 13, 2026, investigated with outside cybersecurity specialists, and ultimately determined that an unauthorized actor accessed and acquired certain files. The formal notification process...

Continue Reading
LLCP Backs Empower in UK Infrastructure Services Push

Updated Category News Views 144

A majority cheque has landed in a business built around unglamorous work that cannot be wished away: keeping mechanical and electrical systems installed, refurbished and maintained. On November 18, LLCP said it completed a majority investment in London-headquartered Empower Technical Services alongside chief executive Nicholas Manning, co-founders Florian Kronawitter and...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 41

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 95

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
Elanco’s $600 Million Buyback Signals a New Chapter

Updated Category News Views 52

Debt coming down and cash coming in finally gave Elanco room to breathe. On Nov. 19, 2026, the animal-health company authorized its first-ever share repurchase program, allowing up to $600 million of common-stock purchases. For NYSE: ELAN, this is more than a flashy capital-return headline. It marks a shift from the ugly but necessary job of balance-sheet repair toward a...

Continue Reading

Top 5 Most Recently Viewed Articles

NN, Inc. Welcomes Tim Erro as Chief Commercial Officer

Updated Category News Views 219

NN, Inc. Welcomes Tim Erro as Chief Commercial Officer NN, Inc. (NASDAQ: NNBR), a leader in high-precision industrial components, has recently appointed Tim Erro as its new Chief Commercial Officer. In this role, Mr. Erro will spearhead NN's global commercial efforts, enhancing the company's strategic initiatives aimed at business growth and development. Under the...

Continue Reading
Horizon Robotics Unveils Innovations in Smart Driving Solutions

Updated Category News Views 321

Horizon Robotics Unveils Innovations at IAA Mobility 2025 Horizon Robotics, a pioneer in smart driving solutions for passenger vehicles, recently demonstrated its cutting-edge technologies at IAA Mobility 2025. This platform not only highlights the company's dedication to smart mobility but also marks a significant step in its global outreach by establishing new...

Continue Reading
Nuvoton Technology Unveils Exciting New Industrial ICs

Updated Category News Views 157

Nuvoton Technology's Innovative BM-ICs for Industrial Applications Nuvoton Technology Corporation Japan (NTCJ) is set to introduce groundbreaking industrial battery monitoring integrated circuits (BM-ICs) designed for 48V batteries. These new products, named "KA49701A" and "KA49702A," are scheduled to enter mass production soon. Enhanced Safety Features in Battery System...

Continue Reading
Celebrate National Coffee Day with Atlas Coffee Club's Free Offer

Updated Category News Views 206

Celebrate National Coffee Day with Atlas Coffee Club Atlas Coffee Club is thrilled to celebrate National Coffee Day with a fantastic offer that every coffee lover is sure to appreciate. From now until October 2, you can snag a complimentary 12-ounce bag of single-origin coffee just by subscribing. All you need to do is cover the shipping fee, and you’re all set! The...

Continue Reading
Crypto Market Dynamics: Bitcoin and XRP Show Potential Gains

Updated Category News Views 264

Bitcoin Approaches Key Resistance Levels Recently, Bitcoin has seen a substantial surge as it has crossed a significant resistance level around $102,000, signifying a bullish sentiment in the market. This progression highlights a critical test as Bitcoin now looks to penetrate a key psychological and technical barrier at $105,000. The macroeconomic backdrop is favorable,...

Continue Reading